A Phase 2a, Randomized, Open-Label, 2-Way Crossover Study To Determine The Pharmacokinetics, Safety, And Tolerability Of Aclidinium/Formoterol 400/12 microg Fixed Dose Combination Via Almirall Inhaler And Formoterol 12 microg Via Foradil Aerolizer In Patients With Moderate To Severe Chronic Obstructive Pulmonary Disease
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Aclidinium bromide/formoterol (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Forest Laboratories
- 29 Aug 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 21 Mar 2012 New trial record